newsfilter
← Latest News
Business Wire·

DiaMedica Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights

DMAC
  • Enrollment completed in the first two cohorts of DiaMedica's Phase 2 early-onset fetal growth restriction (FGR) trial involving 12 participants at 5 µg/kg and 10 µg/kg doses.
  • The ReMEDy2 Phase 2/3 acute ischemic stroke (AIS) trial surpassed the 200-participant enrollment threshold required for its planned interim analysis.
  • A Key Opinion Leader (KOL) event featuring preliminary FGR results is scheduled for November 24, 2026, with experts including Professor Catherine Cluver, Professor Stephen Tong, Professor Susan Walker, and Professor Andrew Shennan.
  • The interim analysis for the ReMEDy2 trial is expected in Q1 2027 after the 200th participant completes their 90-day follow-up.
  • Health Canada authorized the global Phase 2 early-onset preeclampsia study, with DiaMedica preparing to initiate enrollment in Canada and expand to the UK.
  • The European Medicines Agency (EMA) granted conditional authorization in October 2026 for the Phase 2 early-onset preeclampsia trial, enabling potential global expansion.
  • DiaMedica is addressing FDA feedback regarding nonclinical reproductive toxicity data for a U.S. Investigational New Drug application, with pharmacokinetic results expected soon.
  • Cash, cash equivalents, and short-term investments totaled $34.9 million as of September 30, 2026, providing a runway into Q4 2027.
  • Research and development expenses were $9.2 million for the three months ended September 30, 2026, and $25.4 million for the nine-month period, driven by clinical trial expansion.
  • Net losses were $11.3 million for the three months ended September 30, 2026, and $31.5 million for the nine-month period.
  • A conference call to discuss business updates and Q3 2026 financial results is set for November 13, 2026, at 8:00 AM Eastern Time.